Molecular subtyping of feline immunodeficiency virus from domestic cats in Australia

Objective To determine the prevalent subtypes of feline immunodeficiency virus (FIV) present in the domestic cat population of Australia. Method Blood samples were collected from 41 FIV antibody positive cats from four cities across Australia. Following DNA extraction, polymerase chain reaction (PCR) was performed to amplify the variable V3-V5 region of the envelope (env) gene. Genotypes were assessed by direct sequencing of PCR products and comparison with previously reported FIV sequences. Phylogenetic analysis allowed classification of the Australian sequences into the appropriate subtype. Results Of the 41 FIV samples, 40 were found to cluster with previously reported subtype A isolates, whilst the remaining sample grouped within subtype B. Conclusions Subtype A was found to be the predominant FIV subtype present in Australia, although subtype B was also found. These results broaden our knowledge of the genetic diversity of FIV and the associated implications for preventative, diagnostic and therapeutic approaches.

Phylogenetic analysis to define feline immunodeficiency virus subtypes in 31 domestic cats in South Africa

Feline immunodeficiency virus (FIV), a lentivirus, is an important pathogen of domestic cats around the world and has many similarities to human immunodeficiency virus (HIV). A characteristic of these lentiviruses is their extensive genetic diversity which has been an obstacle in the development of successful vaccines. Of the FIV genes, the envelope gene is the most variable and sequence differences in a portion of this gene have been used to define 5 FIV subtypes (A, B, C, D and E). In this study, the proviral DNA sequence of the V3-V5 region of the envelope gene was determined in blood samples from 31 FIV positive cats from 4 different regions of South Africa. Phylogenetic analysis demonstrated the presence of both subtypes A and C, with subtype A predominating. These findings contribute to the understanding of the genetic diversity of FIV

Insulin sensitivity measures in cats exhibit high inter-day variability

In cats with underlying low insulin sensitivity, obesity is a major risk factor for type 2 diabetes. Strategies to prevent the onset of type 2 diabetes could be implemented if these cats could be identified. Currently, two labour-intensive and complex methods have been used to measure insulin sensitivity in research studies: the hyperinsulinemic euglycemic clamp (Clamp) and the minimal model analysis (MINMOD) of a frequentlysampled intravenous glucose tolerance test. However, simpler measures are required in practice. Validation of simple measures requires a wellestablished method with minimal inter-day variability. The aims of this study were to determine the inter-day variability of the current methods of measuring insulin sensitivity in cats, and to assess the relationship between these tests and simpler measures of insulin sensitivity.

Delayed gastric emptying may contribute to prolonged postprandial hyperglycemia in meal-fed cats

Following ingestion of a meal, postprandial hyperglycemia in cats persists for 20–24 hrs, which is much longer than for dogs and human beings, and the reasons for this are unknown. The objectives of this study were 1) to describe the patterns of postprandial plasma glucose, D-lactate, and Llactate concentrations, and gastric emptying time in meal-fed cats and 2) to assess the effects of meal volume on gastric emptying time.

Therapeutic goals for otherwise healthy diabetic cats

The principle goals of treating diabetes in cats are to correct the major clinical signs of diabetes (weight loss, polydipsia / polyuria, and polyphagia or inappetence), and to prevent diabetic ketoacidosis. Additional goals are to minimize the risk of hypoglycaemia by appropriate dose adjustment of insulin or oral hypoglycaemic agents. Appropriate therapy of cats may also lead to diabetic remission, although currently it is not possible at diagnosis to predict which cats are more likely to go into remission. Treatment that is most effective in correcting hyperglycaemia is more likely to lead to remission by facilitating the recovery of the pancreatic cells from glucose toxicity.